Moving on from GWAS: Functional studies on the G6PC2 gene implicated in the regulation of fasting blood glucose

Current Diabetes Reports

Volumn 13, Issue 6, 2013, Pages 768-777

  O'Brien, Richard M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fasting blood glucose; Functional studies; G6PC2 gene; Genome wide association studies; Glucose; Glucose 6 phosphatase; GWAS; Insulin; Islet; Mouse; Secretion

Indexed keywords

GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATASE CATALYTIC SUBUNIT; GLUCOSE 6 PHOSPHATE; HEMOGLOBIN A1C; INSULIN; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT; CARDIOVASCULAR MORTALITY; G6PC2 GENE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRANSCRIPTION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; GLYCOLYSIS; HUMAN; HYDROLYSIS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KNOCKOUT MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BLOOD GLUCOSE; FASTING; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE-6-PHOSPHATASE; HUMANS;

EID: 84889081103     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0422-8     Document Type: Article

References (99)

1. Yaghootkar H, Frayling TM. Recent progress in the use of genetics to understand links between type 2 diabetes and related metabolic traits. Genome Biol. 2013;14(3):203. doi: 10.1186/gb-2013-14-3-203.
2. Torres JM, Cox NJ, Philipson LH. Genome wide association studies for diabetes: perspective on results and challenges. Pediatr Diabetes. 2013;14(2):90-6. doi: 10.1111/pedi.12015.
3. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, Cavalcanti-Proenca C, et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science. 2008;320(5879):1085-8.
4. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, Silver KD, et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest. 2008;118:2620-8.
5. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, et al. Common variants at ten genomic loci influence hemoglobin A1C levels via glycemic and non-glycemic pathways. Diabetes. 2010;59(12):3229-39. doi: 10.2337/db10-0502.
6. El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of personalized obesity therapy. Endocrinology: Nature reviews; 2013.
7. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2006;29(7):1619-25. doi: 10.2337/dc05-2525.
8. Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S194-8. doi: 10.2337/dc09-S309.
9. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med. 2004;19(12):1175-80. doi: 10.1111/j.1525-1497.2004.40178.x.
10. Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013;7(1):14-24. doi: 10.1007/s11684-013-0262-6.
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233-40.
12. Lawes CM, Parag V, Bennett DA, Suh I, Lam TH, Whitlock G, et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 2004;27(12):2836-42.
13. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26(5):968-76. doi: 10.1161/01.ATV.0000216787.85457.f3.
14. • Abdul-Ghani MA, Stern MP, Lyssenko V, Tuomi T, Groop L, Defronzo RA. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. Diabetes Care. 2010;33(3):557-61. doi: 10.2337/dc09-1145. This paper challenges the long held connection between FBG and type 2 diabetes risk.
15. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. doi: 10.1016/S0140-6736(10)60484-9.
16. Cecchini KR, Raja Banerjee A, Kim TH. Towards a genome-wide reconstruction of cis-regulatory networks in the human genome. Semin Cell Dev Biol. 2009;20(7):842-8. doi: 10.1016/j.semcdb.2009.06.005.
17. McMurray F, Moir L, Cox RD. From mice to humans. Curr Diab Rep. 2012;12(6):651-8. doi: 10.1007/s11892-012-0323-2.
18. Frayling TM, Ong K. Piecing together the FTO jigsaw. Genome Biol. 2011;12(2):104. doi: 10.1186/gb-2011-12-2-104.
19. Hansson O, Zhou Y, Renstrom E, Osmark P. Molecular function of TCF7L2: consequences of TCF7L2 splicing for molecular function and risk for type 2 diabetes. Curr Diab Rep. 2010;10(6):444-51. doi: 10.1007/s11892-010-0149-8.
20. van de Bunt M, Gloyn AL. From genetic association to molecular mechanism. Curr Diab Rep. 2010;10(6):452-66. doi: 10.1007/s11892-010-0150-2.
21. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2008;41:77-81.
22. Reiling E, van 't Riet E, Groenewoud MJ, Welschen LM, van Hove EC, Nijpels G, et al. Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk. Diabetologia. 2009;52:1866-70.
23. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105-16.
24. Hu C, Zhang R, Wang C, Ma X, Wang C, Fang Q, et al. A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia. 2009;52(3):451-6.
25. Hu C, Zhang R, Wang C, Yu W, Lu J, Ma X, et al. Effects of GCK, GCKR, G6PC2 and MTNR1B variants on glucose metabolism and insulin secretion. PLoS One. 2010;5(7):e11761. doi: 10.1371/journal.pone.0011761.
26. Tam CH, Ho JS, Wang Y, Lee HM, Lam VK, Germer S, et al. Common polymorphisms in MTNR1B, G6PC2 and GCK are associated with increased fasting plasma glucose and impaired beta-cell function in Chinese subjects. PLoS One. 2010;5(7):e11428. doi: 10.1371/journal.pone.0011428.
27. Wang Y, Martin CC, Oeser JK, Sarkar S, McGuinness OP, Hutton JC, et al. Deletion of the gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein autoantigen results in a mild metabolic phenotype. Diabetologia. 2007;50:774-8.
28. • Pound LD, Oeser JK, O'Brien TP, Wang Y, Faulman CJ, Dadi PK, et al. G6PC2: a negative regulator of basal glucose-stimulated insulin secretion. Diabetes. 2013;62:1547-56. doi: 10.2337/db12-1067. This study complements the related GWAS data by demonstrating that G6PC2 directly regulates FBG.
29. Bonnefond A, Bouatia-Naji N, Simon A, Saint-Martin C, Dechaume A, de Lonlay P, et al. Mutations in G6PC2 do not contribute to monogenic forms of early infancy diabetes and beta cell dysfunction. Diabetologia. 2009;52(5):982-5. doi: 10.1007/s00125-009-1299-6.
30. Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell. 1995;83(1):69-78.
31. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30(11):1512-26. doi: 10.1002/humu.21110.
32. Magnuson MA, She P, Shiota M. Gene-altered mice and metabolic flux control. J Biol Chem. 2003;278(35):32485-8.
33. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274(1):305-15.
34. Matschinsky FM. Glucokinase, glucose homeostasis, and diabetes mellitus. Curr Diab Rep. 2005;5(3):171-6.
35. Mithieux G. New knowledge regarding glucose-6 phosphatase gene and protein and their roles in the regulation of glucose metabolism. Eur J Endocrinol. 1997;136(2):137-45.
36. Foster JD, Pederson BA, Nordlie RC. Glucose-6-phosphatase structure, regulation, and function: an update. Proc Soc Exp Biol Med. 1997;215(4):314-32.
37. van de Werve G, Lange A, Newgard C, Mechin MC, Li Y, Berteloot A. New lessons in the regulation of glucose metabolism taught by the glucose 6-phosphatase system. Eur J Biochem. 2000;267(6):1533-49.
38. Van Schaftingen E, Gerin I. The glucose-6-phosphatase system. Biochem J. 2002;362(Pt 3):513-32.
39. Hutton JC, O'Brien RM. The glucose-6-phosphatase catalytic subunit gene family. J Biol Chem. 2009;284:29241-5.
40. Arden SD, Zahn T, Steegers S, Webb S, Bergman B, O'Brien RM, et al. Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein. Diabetes. 1999;48(3):531-42.
41. Ebert DH, Bischof LJ, Streeper RS, Chapman SC, Svitek CA, Goldman JK, et al. Structure and promoter activity of an islet-specific glucose-6- phosphatase catalytic subunit-related gene. Diabetes. 1999;48(3):543-51.
42. Hutton JC, Eisenbarth GS. A pancreatic beta-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. Proc Natl Acad Sci U S A. 2003;100(15):8626-8.
43. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A. 2003;100(14):8384-8.
44. Han B, Serra P, Amrani A, Yamanouchi J, Maree AF, Edelstein-Keshet L, et al. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med. 2005;11(6):645-52.
45. Mukherjee R, Wagar D, Stephens TA, Lee-Chan E, Singh B. Identification of CD4+ T cell-specific epitopes of islet-specific glucose-6-phosphatase catalytic subunit-related protein: a novel beta cell autoantigen in type 1 diabetes. J Immunol. 2005;174(9):5306-15.
46. Yang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum C, et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol. 2006;176(5):2781-9.
47. Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol. 2008;127(3):359-65.
48. Polychronakos C, Li Q. Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet. 2011;12(11):781-92. doi: 10.1038/nrg3069.
49. Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, Ahlqvist E, et al. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab. 2012;16(1):122-34. doi: 10.1016/j.cmet.2012.06.006.
50. Baerenwald DA, Bonnefond A, Bouatia-Naji N, Flemming BP, Umunakwe OC, Oeser JK, et al. Multiple functional polymorphisms in the G6PC2 gene contribute to the association with higher fasting plasma glucose levels. Diabetologia. 2013;56(6):1306-16. doi: 10.1007/s00125-013-2875-3.
51. Matschinsky FM. Banting lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes. 1996;45(2):223-41.
52. Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009;66(1):27-42.
53. Waddell ID, Burchell A. The microsomal glucose-6-phosphatase enzyme of pancreatic islets. Biochem J. 1988;255(2):471-6.
54. Perales MA, Sener A, Malaisse WJ. Hexose metabolism in pancreatic islets: the glucose-6-phosphatase riddle. Mol Cell Biochem. 1991;101(1):67-71.
55. Trandaburu T. Fine structural localization of glucose-6-phosphatase activity in the pancreatic islets of two amphibian species (Salamandra salamandra L. and Rana esculenta L.). Acta Histochem. 1977;59(2):246-53.
56. Sweet IR, Najafi H, Li G, Grodberg J, Matschinsky FM. Measurement and modeling of glucose-6-phosphatase in pancreatic islets. Am J Physiol. 1997;272(4 Pt 1):E696-711.
57. Martin CC, Bischof LJ, Bergman B, Hornbuckle LA, Hilliker C, Frigeri C, et al. Cloning and characterization of the human and rat Islet-Specific Glucose-6-Phosphatase Catalytic Subunit-Related Protein (IGRP) genes. J Biol Chem. 2001;276(27):25197-207.
58. Khan A, Chandramouli V, Ostenson CG, Low H, Landau BR, Efendic S. Glucose cycling in islets from healthy and diabetic rats. Diabetes. 1990;39(4):456-9.
59. Laybutt DR, Glandt M, Xu G, Ahn YB, Trivedi N, Bonner-Weir S, et al. Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem. 2003;278(5):2997-3005.
60. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes. 1995;44(12):1447-57.
61. Pedersen KB, Zhang P, Doumen C, Charbonnet M, Lu D, Newgard CB, et al. The promoter for the gene encoding the catalytic subunit of rat glucose-6-phosphatase contains two distinct glucose-responsive regions. Am J Physiol Endocrinol Metab. 2007;292(3):E788-801. doi: 10.1152/ajpendo.00510.2006.
62. Petrolonis AJ, Yang Q, Tummino PJ, Fish SM, Prack AE, Jain S, et al. Enzymatic characterization of the pancreatic islet-specific glucose-6- phosphatase-related protein (IGRP). J Biol Chem. 2004;279:13976-83.
63. Ashcroft SJ, Randle PJ. Glucose-6-phosphatase activity of mouse pancreatic islets. Nature. 1968;219(5156):857-8.
64. Khan A, Chandramouli V, Ostenson CG, Ahren B, Schumann WC, Low H, et al. Evidence for the presence of glucose cycling in pancreatic islets of the ob/ob mouse. J Biol Chem. 1989;264(17):9732-3.
65. Chandramouli V, Khan A, Ostenson CG, Berggren PO, Low H, Landau BR, et al. Quantification of glucose cycling and the extent of equilibration of glucose 6-phosphate with fructose 6-phosphate in islets from ob/ob mice. Biochem J. 1991;278(Pt 2):353-9.
66. Khan A, Chandramouli V, Ostenson CG, Berggren PO, Low H, Landau BR, et al. Glucose cycling is markedly enhanced in pancreatic islets of obese hyperglycemic mice. Endocrinology. 1990;126(5):2413-6.
67. Jazmin LJ, Young JD. Isotopically nonstationary 13C metabolic flux analysis. Methods Mol Biol. 2013;985:367-90. doi: 10.1007/978-1-62703-299-5-18.
68. Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, O'Brien RM. Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6-Phosphatase catalytic subunit-related protein. J Mol Endocrinol. 2002;29:205-22.
69. Li X, Shu YH, Xiang AH, Trigo E, Kuusisto J, Hartiala J, et al. Additive effects of genetic variation in Gck and G6pc2 on insulin secretion and fasting glucose. Diabetes. 2009;58:2946-53.
70. Rose CS, Grarup N, Krarup NT, Poulsen P, Wegner L, Nielsen T, et al. A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads. Diabetologia. 2009;52(10):2122-9.
71. Ingelsson E, Langenberg C, Hivert MF, Prokopenko I, Lyssenko V, Dupuis J, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59(5):1266-75. doi: 10.2337/db09-1568.
72. Heni M, Ketterer C, t Hart LM, Ranta F, van Haeften TW, Eekhoff EM, et al. The impact of genetic variation in the G6PC2 gene on insulin secretion depends on glycemia. J Clin Endocrinol Metab. 2010;95:E479-84. doi: 10.1210/jc.2010-0860.
73. Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, Faulk C, et al. Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. PLoS Genet. 2006;2(5):e81.
74. Merrins MJ, Fendler B, Zhang M, Sherman A, Bertram R, Satin LS. Metabolic oscillations in pancreatic islets depend on the intracellular Ca2+ level but not Ca2+ oscillations. Biophys J. 2010;99(1):76-84. doi: 10.1016/j.bpj.2010.04. 012.
75. Merrins MJ, Bertram R, Sherman A, Satin LS. Phosphofructo-2-kinase/ fructose-2,6-bisphosphatase modulates oscillations of pancreatic islet metabolism. PLoS One. 2012;7(4):e34036. doi: 10.1371/journal.pone.0034036.
76. Bertram R, Sherman A, Satin LS. Electrical bursting, calcium oscillations, and synchronization of pancreatic islets. Adv Exp Med Biol. 2010;654:261-79. doi: 10.1007/978-90-481-3271-3-12.
77. Wolf BA, Colca JR, Comens PG, Turk J, McDaniel ML. Glucose 6-phosphate regulates Ca2+ steady state in endoplasmic reticulum of islets. A possible link in glucose-induced insulin secretion. J Biol Chem. 1986;261(35):16284-7.
78. Jetton TL, Liang Y, Pettepher CC, Zimmerman EC, Cox FG, Horvath K, et al. Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. J Biol Chem. 1994;269(5):3641-54.
79. Goh BH, Khan A, Efendic S, Portwood N. Expression of glucose-6- phosphatase system genes in murine cortex and hypothalamus. Horm Metab Res. 2006;38(1):1-7.
80. Frigeri C, Martin CC, Svitek CA, Oeser JK, Hutton JC, Gannon M, et al. The Proximal Islet-Specific Glucose-6-Phosphatase Catalytic Subunit Related Protein (IGRP) autoantigen promoter is sufficient to initiate but not maintain transgene expression in mouse islets in vivo. Diabetes. 2004;53:1754-64.
81. Wang Y, Flemming BP, Martin CC, Allen SR, Walters J, Oeser JK, et al. Long-range enhancers are required to maintain expression of the autoantigen islet-specific glucose-6-phosphatase catalytic subunit-related protein in adult mouse islets in vivo. Diabetes. 2008;57(1):133-41.
82. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci. 2006;361(1471):1219-35.
83. Barzilai N, Rossetti L. Role of glucokinase and glucose-6-phosphatase in the acute and chronic regulation of hepatic glucose fluxes by insulin. J Biol Chem. 1993;268(33):25019-25.
84. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem. 2012;81:767-93. doi: 10.1146/annurev-biochem-072909-095555.
85. Karunakaran U, Park KG. A systematic review of oxidative stress and safety of antioxidants in diabetes: focus on islets and their defense. Diabetes Metab J. 2013;37(2):106-12. doi: 10.4093/dmj.2013.37.2.106.
86. Trinh K, Minassian C, Lange AJ, O'Doherty RM, Newgard CB. Adenovirus-mediated expression of the catalytic subunit of glucose-6- phosphatase in INS-1 cells. Effects on glucose cycling, glucose usage, and insulin secretion. J Biol Chem. 1997;272(40):24837-42.
87. Iizuka K, Nakajima H, Ono A, Okita K, Miyazaki J, Miyagawa J, et al. Stable overexpression of the glucose-6-phosphatase catalytic subunit attenuates glucose sensitivity of insulin secretion from a mouse pancreatic beta-cell line. J Endocrinol. 2000;164(3):307-14.
88. Wang H, Liu L, Zhao J, Cui G, Chen C, Ding H, et al. Large scale meta-analyses of fasting plasma glucose raising variants in GCK, GCKR, MTNR1B and G6PC2 and their impacts on type 2 Diabetes Mellitus risk. PLoS One. 2013;8(6):e67665. doi: 10.1371/journal.pone.0067665.
89. Freathy RM, Hayes MG, Urbanek M, Lowe LP, Lee H, Ackerman C, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: common genetic variants in GCK and TCF7L2 are associated with fasting and postchallenge glucose levels in pregnancy and with the new consensus definition of gestational diabetes mellitus from the International Association of Diabetes and Pregnancy Study Groups. Diabetes. 2010;59(10):2682-9. doi: 10.2337/db10-0177.
90. Bouatia-Naji N, Bonnefond A, Baerenwald DA, Marchand M, Bugliani M, Marchetti P, et al. Genetic and functional assessment of the role of the rs13431652-A and rs573225-A alleles in the G6PC2 promoter that strongly associate with elevated fasting glucose levels. Diabetes. 2010;59(10):2662-71. doi: 10.2337/db10-0389.
91. Sharp PA. Split genes and RNA splicing. Cell. 1994;77(6):805-15.
92. Solis AS, Shariat N, Patton JG. Splicing fidelity, enhancers, and disease. Front Biosci. 2008;13:1926-42.
93. Dos Santos C, Bougneres P, Fradin D. An SNP in a methylatable Foxa2 binding site of the G6PC2 promoter is associated with insulin secretion in vivo and increased promoter activity in vitro. Diabetes. 2009;58:489-92.
94. Dai C, Brissova M, Hang Y, Thompson C, Poffenberger G, Shostak A, et al. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. Diabetologia. 2012;55(3):707-18. doi: 10.1007/s00125-011-2369- 0.
95. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov. 2009;8(5):399-416.
96. Jensen MV, Joseph JW, Ronnebaum SM, Burgess SC, Sherry AD, Newgard CB. Metabolic cycling in control of glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab. 2008;295(6):E1287-97.
97. Chen SY, Pan CJ, Nandigama K, Mansfield BC, Ambudkar SV, Chou JY. The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. Faseb J. 2008;22:2206-13.
98. Wang H, Iynedjian PB. Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. Proc Natl Acad Sci U S A. 1997;94(9):4372-7.
99. Wang H, Iynedjian PB. Acute glucose intolerance in insulinoma cells with unbalanced overexpression of glucokinase. J Biol Chem. 1997;272(41):25731-6.